Sirtuin 6 activating peptides and cosmetic or pharmaceutical composition containing them

1. A peptide comprising a peptide sequence of highly conserved regions of human Sirtuin (SIRT) proteins, of general formula (I):

R 1 -(AA) n -X 1 —X 2 —X 3 —X 4 —X 5 —X 6 -(AA) p -R 2

in which,

X 1 is glycine or threonine or histidine,

X 2 is alanine or glutamine or glycine,

X 3 is glycine or asparagine or serine,

X 4 is valine or isoleucine or leucine,

X 5 is serine or aspartic acid or phenylalanine,

X 6 is alanine or glutamic acid or lysine, and

when X 1 is glycine then X 2 is alanine and X 3 is glycine,

when X 1 is threonine then X 3 is asparagine,

when X 1 is histidine then X 2 is glycine,

AA is any amino acid and n and p are integers between 0 and 2,

R 1 is the primary amino function of the N-terminal amino acid, free or substituted by an acyl type group having either an alkyl chain from C 1 to C 30 , saturated or unsaturated, an acetyl group, or an aromatic group chosen from among a benzoyl, tosyl or benzyloxycarbonyl type group, and

R 2 is the hydroxyl group of the carboxyl function of the C-terminal amino acid, free or substituted by a group chosen from among an alkyl chain from C 1 to C 30 , or an NH 2 , NHY or NYY group with Y representing an alkyl chain from C 1 to C 4 ,

wherein the peptide is one of the following sequences:

(SEQ ID NO: 3)

Leu-Val-Gly-Ala-Gly-Val-Ser-Ala-NH 2

(SEQ ID NO: 4)

Gly-Ala-Gly-Val-Ser-Ala-Glu

(SEQ ID NO: 5)

Gly-Ala-Gly-Val-Ser-Ala-Glu-NH 2 .

2. The peptide according to claim 1 wherein the peptide is (SEQ ID NO: 5) Gly-Ala-Gly-Val-Ser-Ala-Glu-NH 2 .

3. The peptide according to claim 1 , wherein the peptide is solubilized in one or more physiologically acceptable solvents selected from the group consisting of water, glycerol, ethanol, propanediol, propylene glycol, butylene glycol, dipropylene glycol, ethoxylated diethylene glycol or propoxylated diethylene glycol, cyclic polyols, white petroleum jelly, vegetable oil, and combinations thereof

4. A cosmetic composition comprising:

at least one peptide as defined in claim 1 , as a Sirtuin 6 (SIRT6) activating agent, in a physiologically acceptable medium, wherein the peptide is present in the medium alone or in combination with at least one other active agent selected from the group consisting of vitamin C, vitamin B, dihydroepiandrosterone (DHEA), phytosterols, salicylic acid, retinoids, flavonoids, sugar amines, azole compounds, and metallic salts.

5. The composition according to claim 4 , wherein said peptide is present at a concentration of between 10 −9 M and 10 −3 M in relation to the total weight of the final composition.

6. The composition according to claim 4 , wherein said peptide is present at a concentration of between 2×10 −8 M and 10 −5 M in relation to the total weight of the final composition.

7. The composition according to claim 4 , wherein the composition is a topical composition.

8. A cosmetic composition comprising:

a peptide comprising a peptide sequence of highly conserved regions of human Sirtuin (SIRT) proteins, of general formula (I):

R 1 -(AA) n -X 1 —X 2 —X 3 —X 4 —X 5 —X 6 -(AA) p -R 2

in which,

X 1 is glycine or threonine or histidine,

X 2 is alanine or glutamine or glycine,

X 3 is glycine or asparagine or serine,

X 4 is valine or isoleucine or leucine,

X 5 is serine or aspartic acid or phenylalanine,

X 6 is alanine or glutamic acid or lysine, and

when X 1 is glycine then X 2 is alanine and X 3 is glycine,

when X 1 is threonine then X 3 is asparagine,

when X 1 is histidine then X 2 is glycine,

AA is any amino acid and n and p are integers between 0 and 2,

R 1 is the primary amino function of the N-terminal amino acid, free or substituted by an acyl type group having either an alkyl chain from C 1 to C 30 , saturated or unsaturated, an acetyl group, or an aromatic group chosen from among a benzoyl, tosyl or benzyloxycarbonyl type group, and

R 2 is the hydroxyl group of the carboxyl function of the C-terminal amino acid, free or substituted by a group chosen from among an alkyl chain from C 1 to C 30 , or an NH 2 , NHY or NYY group with Y representing an alkyl chain from C 1 to C 4;

wherein the peptide is one of the following sequences:

(SEQ ID NO: 3)

Leu-Val-Gly-Ala-Gly-Val-Ser-Ala-NH 2

(SEQ ID NO: 4)

Gly-Ala-Gly-Val-Ser-Ala-Glu

(SEQ ID NO: 5)

Gly-Ala-Gly-Val-Ser-Ala-Glu-NH 2 , and

a physiologically acceptable medium,

said cosmetic composition for repairing Deoxyribonucleic acid (DNA) degradation, for improving telomere maintenance, or for increasing the expression of keratinocyte differentiation markers and promoting the expression of extracellular matrix proteins by skin fibroblasts.

9. The composition according to claim 8 wherein the peptide is (SEQ ID NO: 5) Gly-Ala-Gly-Val-Ser-Ala-Glu-NH 2 .

10. The composition according to claim 8 , wherein the peptide is solubilized in one or more physiologically acceptable solvents selected from the group consisting of water, glycerol, ethanol, propanediol, propylene glycol, butylene glycol, dipropylene glycol, ethoxylated diethylene glycol or propoxylated diethylene glycol, cyclic polyols, white petroleum jelly, vegetable oil, and combinations thereof.

11. The composition according to claim 8 , wherein said peptide is present at a concentration of between 10 −9 M and 10 −3 M in relation to the total weight of the final composition.

12. The composition according to claim 8 , wherein said peptide is present at a concentration of between 2×10 −8 M and 10 −5 M in relation to the total weight of the final composition.

13. A method for treating cutaneous signs of aging and photo aging on skin, the method comprising:

topically applying, to skin to be treated, a composition comprising an effective quantity of a peptide comprising a peptide sequence of highly conserved regions of human Sirtuin (SIRT) proteins, of general formula (I):

R 1 -(AA) n -X 1 —X 2 —X 3 —X 4 —X 5 —X 6 -(AA) p -R 2

in which,

X 1 is glycine or threonine or histidine,

X 2 is alanine or glutamine or glycine,

X 3 is glycine or asparagine or serine,

X 4 is valine or isoleucine or leucine,

X 5 is serine or aspartic acid or phenylalanine,

X 6 is alanine or glutamic acid or lysine, and

when X 1 is glycine then X 2 is alanine and X 3 is glycine,

when X 1 is threonine then X 3 is asparagine,

when X 1 is histidine then X 2 is glycine,

AA is any amino acid and n and p are integers between 0 and 2,

R 1 is the primary amino function of the N-terminal amino acid, free or substituted by an acyl type group having either an alkyl chain from C 1 to C 30 , saturated or unsaturated, an acetyl group, or an aromatic group chosen from among a benzoyl, tosyl or benzyloxycarbonyl type group, and

R 2 is the hydroxyl group of the carboxyl function of the C-terminal amino acid, free or substituted by a group chosen from among an alkyl chain from C 1 to C 30 , or an NH 2 , NHY or NYY group with Y representing an alkyl chain from C 1 to C 4 ,

wherein the peptide is one of the following sequences:

(SEQ ID NO: 3)

Leu-Val-Gly-Ala-Gly-Val-Ser-Ala-NH 2

(SEQ ID NO: 4)

Gly-Ala-Gly-Val-Ser-Ala-Glu

(SEQ ID NO: 5)

Gly-Ala-Gly-Val-Ser-Ala-Glu-NH 2 .

14. The method according to claim 13 wherein the peptide is (SEQ ID NO: 5) Gly-Ala-Gly-Val-Ser-Ala-Glu-NH 2 .

15. The method according to claim 13 , wherein the peptide is solubilized in one or more physiologically acceptable solvents selected from the group consisting of water, glycerol, ethanol, propanediol, propylene glycol, butylene glycol, dipropylene glycol, ethoxylated diethylene glycol or propoxylated diethylene glycol, cyclic polyols, white petroleum jelly, vegetable oil, and combinations thereof.